Publications
Redding A, Grabocka E. Stress granules and hormetic adaptation of cancer. Trends Cancer. 2023 Dec;9(12):995-1005. doi: 10.1016/j.trecan.2023.08.005. Epub 2023 Sep 11. PMID: 37704502.
Redding A, Grabocka E. A Splendid New Beginning at the End of a 40-Year Quest: The First KRASG12D Inhibitor in Pancreatic Cancer. Cancer Discov. 2023 Feb 6;13(2):260-262. doi: 10.1158/2159-8290.CD-22-1304. PMID: 36744321.
Obesity modulates the Stress Granule Dependence of Pancreatic Cancer.
Fontenenau G, Redding A, Sim E, Hoag-Lee H and Grabocka E. Cancer Discovery 2022; candisc.1672.2021. https://doi.org/10.1158/2159-8290.CD-21-1672
RAS-mediated tumor stress adaptation and the targeting opportunities it presents.
Redding A, Aplin AE, and Grabocka E. Dis Model Mech. 2022 Feb 1;15(2):dmm049280. doi: 10.1242/dmm.049280. Epub 2022 Feb 11. PMID: 35147163.
Stress Granules in Cancer.
Song MS, Grabocka E. Rev Physiol Biochem Pharmacol. 2020;10.1007/112_2020_37. doi:10.1007/112_2020_37
Evaluating Stress Granules in Pancreatic Cancer In Vitro and In Vivo.
Sim E, Irollo E, Grabocka E.Methods Mol Biol. 2019;1882:183-195. doi:10.1007/978-1-4939-8879-2_17
Mutant KRAS enhances tumor cell fitness by upregulating stress granules.
Grabocka E., Bar-Sagi D. Cell. 2016 Dec 15;167(7):1803-1813.e12. doi: 10.1016/j.cell.2016.11.035.PMID:27984728
Kamphorst JJ, Nofal M, Commisso C, Hackett SR, Lu W, Grabocka E, Vander Heiden MG, Miller G, Drebin JA, Bar-Sagi D, Thompson CB, Rabinowitz JD.
Cancer Res. 2015 Feb 1;75(3):544-53. doi: 10.1158/0008-5472.CAN-14-2211.
Molecular pathways: targeting the dependence of mutant RAS cancers on the DNA damage response.
Grabocka E*, Commisso C, Bar-Sagi D.
Clin Cancer Res. 2015 Mar 15;21(6):1243-7. doi: 10.1158/1078-0432.CCR-14-0650. Epub 2014 Nov 25. Review.*Corresponding Author
Grabocka E, Pylayeva-Gupta Y, Jones MJ, Lubkov V, Yemanaberhan E, Taylor L, Jeng HH, Bar-Sagi D.
Cancer Cell. 2014 Feb 10;25(2):243-56. doi: 10.1016/j.ccr.2014.01.005.
Martz MK, Grabocka E, Beeharry N, Yen TJ, Wedegaertner PB.
Mol Biol Cell. 2013 Sep;24(18):2785-94. doi: 10.1091/mbc.E12-07-0533. Epub 2013 Jul 24.
Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells.
Commisso C, Davidson SM, Soydaner-Azeloglu RG, Parker SJ, Kamphorst JJ, Hackett S, Grabocka E, Nofal M, Drebin JA, Thompson CB, Rabinowitz JD, Metallo CM, Vander Heiden MG, Bar-Sagi D.
Nature. 2013 May 30;497(7451):633-7. doi: 10.1038/nature12138. Epub 2013 May 12.
RAS oncogenes: weaving a tumorigenic web.
Pylayeva-Gupta Y*, Grabocka E*, Bar-Sagi D.
Nat Rev Cancer. 2011 Oct 13;11(11):761-74. doi: 10.1038/nrc3106. Review.*Equal contribution
Raf-1 and squamous cell carcinoma: Rok-ing the boat.
Grabocka E, Bar-Sagi D.
Cancer Cell. 2009 Aug 4;16(2):85-6. doi: 10.1016/j.ccr.2009.07.012.
Grabocka E, Wedegaertner PB.
Mol Pharmacol. 2007 Oct;72(4):993-1002. Epub 2007 Jul 3.
Functional consequences of G alpha 13 mutations that disrupt interaction with p115RhoGEF.
Grabocka E, Wedegaertner PB.
Oncogene. 2005 Mar 24;24(13):2155-65.
Research Highlights
'Elda Grabocka: Stress-buffering comes in granules' by Lucia Morgado-Palacin;. J Cell Biol 7 February 2022; 221 (2): e202201081. doi: https://doi.org/10.1083/jcb.202201081
'Coping with stress' by Sarah Seton-Rogers. Research Highlight, Nature Reviews Cancer, January 27, 2017
'Mutant RAS calms stressed-out cancer cells' by Kirsten Bryant and Channing Der. Developmental Cell, January 23,2017
'Wild type Ras: Keeping mutant RAS in CHK' by Theonie Anastassiadis and Eric Brown, Preview, Cancer Cell, February 10, 2014.
'HRas and NRas regulate the DNA damage response in KRas-mutant tumors', Cancer Discovery, April, 2014.
'Blind spot found in deadly K-Ras tumors' by Philippa Bourke, Chrysalis, February, 2014.
Media Coverage
'Stress coping mechanisms help mutant KRAS cancer cells resist chemo' by Megan Brooks, Reuters Health, December 21, 2016.
'Coping mechanisms suggest new way to make cancer cells more vulnerable to chemotherapy' by Gregory Williams, NYU Medical Center Press Release, December 2016
'Weakness exposed in most common cancer gene' by David March, NYU Medical Center Press Release”, February, 2014.
http://communications.med.nyu.edu/media-relations/news/weakness-exposedmost-common-cancer-gene
'Targeting 'undruggable' cancer mechanism can make chemo more effective' by Emily Mullin, Fierce Biotech Research, February, 2014.
'Making K-Ras cancers druggable', Hematology Times. February, 2014.